AUTHORS
Mengyang Di, MD, PhD, Brian G Till, MD2, Chaitra Ujjani, MD3, Mazyar Shadman, MD, MPH4, Stephen Douglas Smith, MD5, Paul S Martin, MD6, Jennifer J. Huang, MD, PhD7, Chen Zhang, MD, MS, FACP8, Ajay Gopal, MD9, Ryan C Lynch, MD10
AFFILIATIONS
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
9 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
10 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
ABSTRACT
Background: RCHOP cures approximately 60-70% patients with large B cell lymphoma, but patients with high-grade features experience poor outcomes and often receive more intensive regimens including DA-EPOCH-R. Despite this intensification of therapy, the complete response (CR) rate is only 60-70% with a two-year progression-free survival (PFS) of approximately 50% following DA-EPOCH-R in high grade B cell lymphoma ([HGBCL], Atallah-Yunes Haematologica 2025, Petrich Blood 2014). Survival rates after relapse are poor, especially in cases of early treatment failure, necessitating improvements in 1st line therapy.
Epcoritamab is a CD3XCD20 bispecific T cell engager (TCE) approved to treat patients with diffuse large B cell lymphoma (DLBCL) in the 3rd line and beyond (Thieblemont Leukemia 2024). Epcoritamab has also demonstrated high efficacy when given in combination with R-CHOP in patients with previously untreated DLBCL, including a CR rate of 87% (Brody ICML 2024). To translate this efficacy to the population of greatest need, we designed the present trial which examines safety and efficacy of epcoritamab with DA-EPOCH-R in patients with high-risk aggressive B cell lymphoma.
Methods:
This is a single-center, single-arm trial, conducted at Fred Hutchinson Cancer Center, in Seattle, WA, and registered on clinicaltrials.gov as NCT07097363.
The study enrolls adult patients with untreated aggressive B cell lymphoma where DA-EPOCH-R is indicated as the standard of care, including HGBCL, primary mediastinal B cell lymphoma, Burkitt lymphoma, and grey zone lymphoma. Patients must have measurable disease, ECOG performance status 0-2, and adequate organ (including LVEF ≥50%) function. Transformed lymphomas are permitted, provided no prior systemic therapy for indolent disease. Patients with known CNS involvement are excluded. Pre-treatment prednisone is permitted if clinically indicated. Enrollment of patients who underwent urgent treatment with one cycle of DA-EPOCH-R outside this trial is permitted, provided that the next cycle will not be delayed by >7 days, to ensure representativeness of the study population.
DA-EPOCH-R will be administered per standard protocol every three weeks. Eligible patients will start epcoritamab on C1D8 following the standard step-up dosing schedule (0.16 mg on C1D8, 0.8 mg on C1D15, 48 mg on C2D1, and 48 mg onwards). Epcoritamab will be administered weekly during C1-C4, and every three weeks on day 1 during C5-C6.
The accrual goal is 18 patients. The primary endpoint is dose-limiting toxicities (DLT) prior to C3D1. DLTs are defined as 1) ≥grade 3 (G3) cytokine release syndrome, 2) ≥G3 immune effector cell associated neurotoxicity syndrome, 3) ≥G3 thrombocytopenia with ≥G2 bleeding, 4) AST or ALT elevation ≥ 3 x upper limit of normal (ULN) AND total bilirubin elevation ≥ 2 x ULN in the absence of an alkaline phosphatase ≥ 2 x ULN, 5) ≥G3 non-hematologic toxicity lasting >72 hours, 6) treatment delay of >14 days following C1 due to prolonged recovery from observed toxicity. A prespecified suspension rule was designed to be triggered if the lower limit of an 80% confidence interval could not exclude a DLT rate exceeding 20%. Secondary endpoints include being unable to complete 6 cycles of therapy for reasons other than progression, relative dose intensity of epcoritamab administered, CR, and 1-year PFS. The analyses will be primarily descriptive.
Potential significance: The study will provide important early safety and efficacy data on incorporating TCE with intensive chemoimmunotherapy (DA-EPOCH-R) in patients with high-risk aggressive B cell lymphoma where DA-EPOCH-R is indicated per standard of care. It has the potential to provide key safety and efficacy data for use in design of larger trials of bispecific + intensive therapies for this high-risk population.
DISCLOSURES
Mengyang Di, MD, PhD: Merck - Honoraria; Eli Lilly - Research Funding; BeOne - Research Funding; AbbVie - Research Funding; Regeneron - Research Funding; Schrodinger - Research Funding; Dren Bio - Research Funding; Incyte Corporation - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony)